0000950103-12-001715.txt : 20120403 0000950103-12-001715.hdr.sgml : 20120403 20120403123133 ACCESSION NUMBER: 0000950103-12-001715 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20120402 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20120403 DATE AS OF CHANGE: 20120403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-29630 FILM NUMBER: 12736279 BUSINESS ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP BUSINESS PHONE: 441256894000 MAIL ADDRESS: STREET 1: HAMPSHIRE INTL BUSINESS PARK STREET 2: CHINEHAM BASINGSTOKE CITY: HAMPSHIRE ENGLAND RG STATE: X0 ZIP: R924 8EP FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 dp29719_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 2, 2012

Shire plc
_________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands
_________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486
(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland
_________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700
_________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 8.01. 
Other Events

Shire plc has issued the press releases attached hereto as Exhibit 99.01 and 99.02 which are incorporated by reference herein.


Item 9.01. 
Financial Statements and Exhibits

 
(d)  Exhibits.  The following exhibits are filed herewith:

99.01 
Press Release dated April 2, 2012
99.02 
Press Release dated April 2, 2012
 
 
 
 

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized..


 
SHIRE PLC
  
     
     
 
By:
/s/ A C Russell
  
   
Name:  Angus Russell
  
   
Title:    Chief Executive Officer
  
Dated: April 2, 2012
 
 
 
 

EXHIBIT INDEX
 
Number
 
Description
99.01
Press release dated April 2, 2012
99.02
Press release dated April 2, 2012
 
 
 
 
EX-99.1 2 dp29719_ex9901.htm EXHIBIT 99.1
 
Exhibit 99.01
 
 
 
Press Release
www.shire.com
  
 
Annual Information Update

 
April 2, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2011 and March 31, 2012 (save for the final item under section 3 below which has been deemed as having been filed on March 31, 2011).

The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date.  The information appears by way of record and the Company is under no obligation to update it.

1.  
Announcements made via a RIS

The documents listed below were published via a Regulatory Information Service on or around the dates indicated.

30-Mar-12
  
Shire Announces Top-line Results of the PREVENT2 Trial
22-Mar-12
  
2011 Annual Report - DTR 6.3.5 Disclosure
15-Mar-12
  
Shire to acquire FerroKin BioSciences, Inc.
15-Mar-12
  
Shire Update on US BLA Filing for REPLAGAL®
06-Mar-12
  
PDMR Share Dealing
01-Mar-12
  
Total Voting Rights
01-Mar-12
  
Elections for Interim Dividend
29-Feb-12
  
Director/PDMR Share Dealings
28-Feb-12
  
PDMR Share Dealing
27-Feb-12
  
Director Declaration
24-Feb-12
  
PDMR Share Dealings
23-Feb-12
  
PDMR Share Dealings
22-Feb-12
  
Director/PDMR Share Dealings
09-Feb-12
  
Another strong year for Shire
01-Feb-12
  
Total Voting Rights
31-Jan-12
  
Full Year 2011 results date notification - Feb 9, 2012
23-Jan-12
  
Holding(s) in Company
05-Jan-12
  
VENVANSE Marketing Application accepted for review in EU
03-Jan-12
  
Total Voting Rights
30-Dec-11
  
Director/PDMR Shareholding
15-Dec-11
  
Shire plc Board and Committee Changes
14-Dec-11
  
Director/PDMR Shareholding
12-Dec-11
  
Director/PDMR Shareholding
01-Dec-11
  
Total Voting Rights
01-Dec-11
  
Director/PDMR Shareholding
24-Nov-11
  
Block listing six monthly return
21-Nov-11
  
Director/PDMR Shareholding
07-Nov-11
  
Director/PDMR Shareholding
02-Nov-11
  
PDMR Share Transactions
01-Nov-11
  
Total Voting Rights
01-Nov-11
  
Director Declaration
28-Oct-11
  
Continued strong product sales performance in Q3
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
 
 
13-Oct-11
  
3rd Quarter Results Notification
03-Oct-11
  
Total Voting Rights
30-Sep-11
  
Director/PDMR Shareholding
26-Sep-11
  
Director/PDMR Shareholding
01-Sep-11
  
Elections for Interim Dividend
01-Sep-11
  
Total Voting Rights
25-Aug-11
  
Regulatory Approval
12-Aug-11
  
Purchase of Shares by Employee Benefit Trust
11-Aug-11
  
Half Yearly Report
03-Aug-11
  
Director/PDMR Shareholding
02-Aug-11
  
Director/PDMR Shareholding
01-Aug-11
  
Director/PDMR Shareholding
01-Aug-11
  
Total Voting Rights
29-Jul-11
  
Holding(s) in Company
28-Jul-11
  
Shire’s quarterly revenues grow by 25%
27-Jul-11
  
Board Changes
15-Jul-11
  
Second quarter 2011 results date notification
07-Jul-11
  
Shire files lawsuit against Watson and Roxane
01-Jul-11
  
Shire files lawsuit against Sandoz and Amneal
01-Jul-11
  
Total Voting Rights
28-Jun-11
  
Shire completes acquisition of Advanced BioHealing, Inc.
24-Jun-11
  
Purchase of Shares by Employee Benefit Trust
21-Jun-11
  
Director/PDMR Shareholding
17-Jun-11
  
Director/PDMR Shareholding
01-Jun-11
  
Total Voting Rights
25-May-11
  
Shire receives VYVANSE(R) Paragraph IV Notice Letters
24-May-11
  
Block listing - Six Monthly Return
19-May-11
  
Shire receives VYVANSE(R) Paragraph IV Notice Letter
18-May-11
  
Shire to acquire Advanced BioHealing
09-May-11
  
Director/PDMR Shareholding
06-May-11
  
Purchase of Shares by Employee Benefit Trust
04-May-11
  
Director Declaration
03-May-11
  
Total Voting Rights
28-Apr-11
  
Shire delivers a strong first quarter performance
26-Apr-11
  
Result of AGM
20-Apr-11
  
Notice of Results
19-Apr-11
  
Holding(s) in Company
06-Apr-11
  
Shire files lawsuit against Watson Pharmaceuticals
01-Apr-11
  
Director/PDMR Shareholding
01-Apr-11
  
Total Voting Rights
01-Apr-11
  
Annual Information Update
 
2.  
Documents filed with the Securities and Exchange Commission (“SEC”)

The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ.  Full details of these filings can be found on the SEC’s website at www.sec.gov.

 
2
 

3. 
Documents filed with Companies Registry, Jersey
 
Date of Delivery    Document  
24-Feb-12   Annual Return  
17-May-11 Special Resolutions passed on April 26, 2011  
31-Mar-11 Annual Report and Accounts for the year ended December 31, 2010  
 
 
4. 
Documents sent to Shareholders

The following documents were published and sent to shareholders, and are available on the Company’s website.
 
Date of Delivery    Document  
22-Mar-12 Annual Report and Accounts for the year ended December 31, 2011  
22-Mar-12 
Notice of 2012 Annual General Meeting
  
 
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.


Tony Guthrie
Deputy Company Secretary


For further information please contact:

Investor Relations
    
Eric Rojas
erojas@shire.com
+1 781 482 0999
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157


Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 3
EX-99.2 3 dp29719_ex9902.htm EXHIBIT 99.2
 
Exhibit 99.02
 
 
Press Release
www.shire.com
  
 
April 2, 2012 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,  in accordance with DTR 5.6.1 of the FSA’s Disclosure and Transparency Rules, notifies the market of the following:

At close of business on March, 30 2012, Shire plc's issued voting share capital consisted of 562,532,330 ordinary shares with a nominal value of 5 pence.  Each ordinary share carries one voting right.  Shire plc does not hold any shares in Treasury.

The above figure (562,532,330) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Shire plc under the FSA's Disclosure and Transparency Rules.

 
Tony Guthrie
Deputy Company Secretary
 

 
For further information please contact:

Investor Relations
    
Eric Rojas
erojas@shire.com
+1 781 482 0999
Sarah Elton-Farr
seltonfarr@shire.com
+44 1256 894157


Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.
 
 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
 
 
 
GRAPHIC 4 logo.jpg GRAPHIC begin 644 logo.jpg M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$``("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(" M`@("`@,#`@(#`@("`P0#`P,#!`0$`@,$!`0$!`,$!`,!`@("`@("`@("`@," M`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,# M`P,#`P,#`__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$! M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,` M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I M*C0U-CH.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1 M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`#8`Q`,!$0`"$0$#$0'_V@`, M`P$``A$#$0`_`/W\H`*`"@`H`^=/VB?VF?A_^S?X=M]3\4-/JOB'5Q,OAGP; MI'2I4*-O:UI MI\E.^R26LIOI!>K:6ISXC$T\+%.7Q/X8K=_Y+S/QX\7_`/!0;]IWXC:RVF>! M9;#P9#>.RZ?H'@SP_'KVN-$N<&74M5M;RXGD"?-));VUK&.6VJHX_3,-P9D& M!I*>+4L2X_%4K5'3IW\HP<8I=DY2?FSR9X_$R=J=J?915W^-_P`D>;W'[6W[ M5_A6[,=W\:M7?45=OM&F2_\`",:X;-_XHKQ8]*GM;:8'K`LK.O1E0\5W1X;X M=KQ]S*H*'22]K3OYQO.,FO.UGT;,_K6*@_XSOV]W3\+%?P?^TAKWB7Q9"W[0 M?Q*^.VN^$KITCFD\`>/I?#%UHK/("]Z-&L[1+?4;5%.3;6YM90%RC.?D:L3D M='#X9K)'OA[JGPYA^&_Q<^`7QN^('Q"^&OB/Q-X/T[Q%X(\<^*'\:Z/K_`(8\8:[9 M>'I]5\.ZA?P)=Z+K^F7.HQ7#0L=W^B7$4VQHVB?\[K8RGC7CLMSC*PG3JT:BXWO=>I&FZ7LZN'K2G3;BG&4N9-2: M5U?5-7N?"_BC_@H_^T7H_B?Q+I%G#\//LFD^(=;TRT,OAF_>7[-I^IW5I;F5 MUUU0TAAA3:I3IS=JL4KR@I.R]GM=G%+,,0I M224+)M+1]'ZGZZ?LR?$;Q%\6?@;X!^(7BM=/3Q!XCLM2N-172K:2RT\26NNZ MIIT7V>VEGF:)?L]G%D&1LMN/&<#\VS[`T,LS;&8+#IPD[M) M+>3Z+0]7#5)5*%.I*RD[[:+=H]XKR#<*`/RZ_;8_:^^+GP`^*6@>#_`4?A-M M(U'P-8>(;DZ[HUUJ%W_:%SKFO:?((YH-3ME2W^SZ;;X0H2&WG=\V!]_PKPUE MN<9?6Q.+=95*=>5->SFH+E5.G):.$M;R>M^QYN,Q57#U(PI\MG%/5=;M=_(Z M3]AK]JCXH_M"^)?'^D_$"/PQ':^&=#T74--_L#2;G393<7]_>6T_VEY]1N1+ M'Y<";0`F#DY.:PXLX>R_(Z&#J8)U>:O4G&7M)J2M&*:M:,;:L>!Q56M*HI\J M44FK*W5^9^D-?#GHA0`4`%`!0`4`%`!0`4`%`!0`4`%`'DOQ@^-WPX^!?AE_ M%'Q#U^'2[=B\6EZ5`%NM>UZ\5T5Y;O[*;,JM:G0CS5))_#EA#_Q*]&\+>&I66'2+:2,M MZ2*/2;. M?3M-1HI6^S,-F?"XDS;%Y/BJ-"-98S,O9JK/$58)TJ/.VHPPF&=Z5*UKNI)3 MJNZ7-N=.$H0K0E+E]G23LH1=F[;NVSA<)*([_4+NUG8-@E9K>0-W'->!0XSX@H5%*6,5>*> ML*M.FXONO=C&2^4D=,L!A6K*GR=G%M6_%K\#\*?C[\']2^`OQ3\1?#;5+]-2 M32S;7VCZN(UMO[6T'4XOM.F7TEN&(@N=F^">-695GMI@A*;2?US)LSIYOE]# M'4H>RY[QG"]^2I%VE%/2ZZQ?6+5];GB5Z+PU65)OX=GMH]O3S\S](?\`@EM\ M0+C4D^(?PFU-TOM,T;^S/B!X:@N-DZ:5=37;:9K7V57SY(>Z;2[E=F-DK3R# MYI6-?#^(&"C3>"S&DO9U*G-AZK6G,DN>%[>7/%]U9;(]#+)_Q*6ZC:45VOH_ MQLS\I?'7_(\^-O\`LI6&H6&J6D&H:7?6>HV%RGF6U[87,-W:7$9.-\%S;N\*_B7>:W;:YI^@6^@V MD>F^*TT&`Z7;W^H7\3-:&-O,E^U:A=@RYY`5?X*^@RCB'-LHPT\-@(4W1G4= M1\U'G?.XQB];JRM%:?/J9;O;^QTNSGU#4;VTTZPM8S-XFBMK>!&DFFGD2&&&-1N>221R%C0#)+,0!WKD2 M;:C%-MZ)):W\DB]O)+Y6/);W]H'X%:;>_P!FWWQB^&=K>[MAMI/&WAU71^FR M3&H$1-GC#E:]&&2YO*'/#+,4X=U0J?A[NOR,77H)\OM8)]N9?YGI6C:[HGB& MRCU+P_K&E:YITG$5_H^H6FIV4AP"0EU9321,<$'AN]<-6C5P\W3K4IT)Q^S. M+A)?*23-8N+7NM->3T_`U:S&%`!0`4`%`!0!\A_M%_M4Z=\)K[3_`()GMCNL[7;F5+7='++&C2,T%N#<+]+DG M#T\PA/'8RK]0RC#W=7$2TYK;QI)[OHY6:3T2E+W3DQ&)5%JG3CSUY?#%=+]7 M;;T_34Y;X+?LH:@OB5/C7^TIK$7Q/^--[LN;*SN]ESX/^'J%O.@TWPYIFT6L MEU:YVBX6(0Q.";9"X^TR]&:<105!Y5D5)Y?E<-)26E;$]'*I+XDI=K\S7Q.W MNJ:.%:E[;$/VE;HOLP\DMOZT[GY`_MJ:)X]T+]HWX@0>/=1U75I+W4)-4\(Z MCJ4C/!)X*OY'GT.UTE0!#!8V*,]B\,"JJSVRG_`.`S]W[IGI0S*@])1E3?I=?>M?P/ MI/1[S]E;]HF]&NZ;'\(_BEK,=HEJ9KO3]"U;Q%!8VYDEC@GLM3MO[1MK:-I9 M6"R0HJEWZ9->%4AQ#D,RZE>]HRJ0IN3M=IP?(V]-G=G3'ZK7?-'DJ/T M3=O1ZH]4\)_"SX:^`KVYU'P5X"\(>$K^[M?L5W>^'?#^EZ/=7%GYJ3_99Y[& MVB>6#SHXWV,2NY%.,BO/Q&88[%PC3Q6,K5X0?,HU*DYJ+M:Z4FTG9M7\S2%* MG2=Z=.--]TDOR/Y6/'7_`"//C;_L#X+NXN?$UY>ZUJ M.J3:KXDN+4(L.CP?;HK>"UN)8[<-"\DF^1U\KR)8'*0>._@ MW\3OA8MC_P`+$^'GB/P;!J3/%I\^L::L5A=RQKO>W@OK9Y;5KA4RQA\T2;06 MVX!->E@\SP&/Y_J.-I8ET]9*$O>BGU<7:5O.UO,RG1J4;<]-TUTNK+_(]P_9 M!_:'\3?`SXG^'+,:M=GX<^)]9L-%\7^')IY)-+AM]3N([*/Q!8VK-LLM4L)I MHYS+"$,T,)3P!_R)\3_`-A<_P#TU1-\S_CPZ>XO_2I&%^PWG_A"_P!KWEO^2$:IC+,< M?\2[Q+TR>*VXL_WKAKI_M\/_`$JF3@O@Q?\`UZ?ZGY]VC!)K5G=U2.:W=SO< M[461&8X#=E!.*^RDM))+6S_%'`NA]-_M,_M->,/V@/%4T#:AJ&G?#G2YA9># M_!D,LD5K);6RB&+5]8M(2!J>N784S,9A(+=9!#"%",TG@Y#D.&R7#IJ$98Z: MYJU>RNF]7"#?P4X[:6YG[TKWTZ<1B)UIVNXTUI&/IU:[O\#UW]@#Q9H_PF^( MWQ0\>>-4N]$\/^&O@OKFI7DUQ8SVTTZIXJ\(I;V5A'<1Q_:;ZZNGAMX(5.7E MF1<@$D>;QEAJN8X'+\'A+5*U?&TXQ2DFE>E6O*5KVC%7E)]$F;8"4:-2I.?N MQA3;VM]J.B]3QK]H/]J;XG?M":[=/K&IWNB>"A'L!DM&*I4XU,5;]YB)I.;=M>2_\."Z* M-G;63;,:^)J5Y:MQAT@M%\^[_I%;2/V.OVE=8T--?T[X,>)AIDD"W,$=T-(T MO4KBW=!)')!HNH:A!?,'0@JIMU8@C`Y%.IQ-D5&JZ$\TI*:=FX\\HI];SC%P MT_Q"6#Q'+S1HNWR3^ZZ9PW@+XC?%3]GWQG+?>$]3UOP1XCT>^-KK?AZ^AN;6 MSNI+:0&XTGQ-X]A/'+%=6LK#+P7*!OWB2!?P_/,HJY)C MZF$FW*G;GHU+6YZ4F^5]E)-.,TMI)]&CZ'#UXUJ:G%1[W7CFX M4`%`!0!\.?M>_M4S_!VVTWX:?#.W'B'XX>./LUGX?TJU@74#X692J8['/ZOE.$O*I)OD]HXKFE",N MD8K6I-;+W8^\].+%XGV*5*DKUIZ)+[-^MN[Z+YO0W?V5/V7;;X*Z==^-_'%T M?%?QP\:J]_XR\5W\YU&?3I+]AS99HUE(^U7:D-=21C&+>.&-,>(<_ MEFCT'Q_I#2W%AYLFA^(=-D6R\0^'[B8*))=-O M_+<>3)M3S;6=)K>78I>,LBLGJY3G..R6LZN"J(U3&0C-()M,N7'3?]IM`QYV*#Q^CX'C[+JJC''8>I@I]90_>T_P`.6HO3 MEEZL\JIEE6'\*2DNB?NO_+\CXF\=_`3XT_#(2R>./ACXPT"S@9E?53I4NHZ( M-OWF&M:0;JR"8YW-.O'-?58/.,JQME@\?1J2?V.=0G_X!/EE^!Q3H5J7QTI0 M7>VGWK0\KT^^N],O+75-)OKK3=1M)%GLM2TVZFLKZUE0ADEM;RTD26%PP!#( MXZ5Z,X1E&5.I!2IM6E"23BT^CB]'\T9IN+3B[..S6C7W'[E?L$?M=^(/BK-= M_"/XGWXU+QII.EOJGA?Q-*JQWGB;2+(QQZA8ZL(PJ3:Y9))%,+A54W,'FO(/ M-MW>;\EXPX:HY:HYEE\/986I/DJTE\-*D>)K>TA36?'VLZWK6K7PC`N9[?3M4N]"TFS>7& MYK:WMM/DDC3.U7O9V',C9_'^-\74K9W4H.35+!0IPA'HG*"J3E;O)RLWU45V M/=R^"AAU)*SFVW\FTOZ\SV']L'PKIOBW]FSXMV.HVT,QTOPEJ'B73I)45GLM M4\-Q_P!L6=W;L1F&8-:/'N7!*3R(?ED8'S.&<14PN>Y;*G)QYZT:4DM+PJOD MDGY:W]4GNC7%P3PU5-;1;7DUJ?S$([1M'(AVLCI(I'&&5@RD?0@5^]M;KIV] M3YL_0O\`X*1SR77Q;^&ES*N&O^P^' M_I5(6"^#%_\`7I_J?GHI`12>@0$_0"OLS@/Z&_V'OV:/!WPU^%?A7QYK&@:? MJ7Q'\;Z3:>);S6=2M(;J[T/3=5B2\TC1=',ZM_9T<>GR6TD[PA))9YI=[%$C M5/Q;BO/<3C+_\`!4_QIWOM2 MTRQTK2H]8EE\3A$AT:>XLY+F%3!:-+<7:N6.V>UMSM../N\_PN88W+*V#RV4 M*=>NXQE*<^1*EO-)I/66D7WBY'G8:=*E6C.JGRPNTDNO333;?U/U^_X>;?LV M?\^_Q*_\(^'_`.7-?FG^H6>]\+_X.?\`\@>M_:6'_O\`_@/_``3\R_VT_C%\ M'?CGXY\.^//A=::_9:HVBRZ1XR&N:''HQOI+":-M"OT:.]G^UW(M)[JUD8[2 ML5I:KD@#;]YPME>9Y/A*^#Q\J;IJ:G0]G4Y^7F3]I'X8\JNE)=W*3/-QE6C6 MG&=).+M:5U;T>_JCV[_@EUXVNM*^+/C7P&TSC3/%G@\ZTEMN/EC6/#-_;)%, M$Z!VTW5KY6(ZB*,'.T8\KC_"1EEN%Q:5IX:MR-_W*L7=?^!0C][[FV63Y:LZ M>RE&]O-/_)L_=.OR0]L*`"@#S'XR_$W2O@W\,O&'Q'U=!-;^&=)EN;6QWB-M M2U6=TM-'TN-L@JUWJ=Q:PEADJLC/@A#7?E>`J9EC\-@:3Y77FDY?R07O3G_V M[%-^;TZF5:HJ%*=1[16BVUZ+YL_,7_@GSX"U3XN_$?XA?M2?$F0ZUKD&LW&E M>'KBZ3=`OB34+1)]9U"TC8D01:7HUSI^FV4:C;#'>2A<-"I'WO&>,IY7@<%P M_@%["BX*=1+1^RB[0BWU=2:E4F]Y.*OHV>=@*;J5*F)J:M.T?5[OY)V7J?L1 M7YF>L<9\1M1UW1_A]XYU;PN8AXDTOPAXDU'0//MQ=0_VS8Z/>76F^;:EE%Q' M]LBAS%D;Q\N>:ZL#"C/&82G7O["=:E&I9\KY)3BI6?3W6]>A%1R5.;C\2BVO M5*ZT]3\$%_X*/_M1E5/]M>"1E0?^1+MQC(ST^W5^P?ZC\/\`_/JO_P"#W_\` M(GA_VAB>\?\`P'_@G[9_LX_%'_A*V\3Z M>39ZY;&T1V^Q_P"FPR2)"3Q%-$PRKJ3^5YYE_P#9>:8S!QBX4JSAZOM:-.=]6M;:6?73IJ>VNB2(TB: M5%%9V%^^E)IUQ!K\6G0!8[2Z9KY[>X>)$28M`S#S%=I/UG@3,\;C*.,PF)J2 MK4L(J;I3FVY1Y^9.FY/5KW>:*;;6JV:2\7,:-.E*G."4'*]TM.VMOGKW/F3] MB-]0B_:F^$7]G;Q*VL:M']Q6H?ZOYDI M[*$&O\7M8):.+/]ZX:_[#X?\` MI5(6"^#%_P#7I_J?GD?]2?\`KD?_`$"OM.OS.`_K?^'"JOP\\!JH"JO@SPNJ MJ!@*HT.Q```Z`#BOYPQW^^XS_K_5_P#3DCZJG_#A_AC^2/RK_P""K>BW6/@O MXB56-C&_C'0Y7`.V&[F30]0ME9N@,L-M>$#C/V=J_0O#NK%?VI0^&7[FHEY+ MVD7]S:^\\S-(V]C):)Z3!97%U\<&%HQK552E)PT;5K;K6WW79^E?\`PZF^'O\`T5OQ MU_X*?#G_`,CU\+_Q$/&_]"W#_P#@=7_,]'^RZ?\`S]E]R,W4O^"8'PET6.*7 M6/CCXHTF*9S'#)J5OX2L(Y9`I<3X_,\`\'B;8;!TJ%15(57)I-6TZ^A^A-?&'>%`!0!\$?\`!2#0O$6L_LVW M;Z#:7=Y;:)XP\.ZYXCALXWE>+0+2/4H9KR6*)2S6MM?W6GS2MC$:1F5L+&Q' MV'`]6A0SR*JR5-U:-2G2;T7M&XM13?645)+NW9:LXZ,UJT94(+9S_`';?^&,K M2E_VZGW)4X7Y8R5_+6WK;1'\]'[8G[,.O_`/Q[JFL:9IMS2TT26_EDN)/"NKRH"+*ZM9&=+5Y=J7-NL91C*DJ1_M'#.?4&EAYMQ7[J3O%]K_`&7V\NZ/)_@S M^T3\6?@'?75U\.?$8LK#4I(YM6\.:I;+J?AS5)8E")<7&G2.AM[P1@)]JM9; M>;:`K.R@*/2S3),NSB$8XVAS3IJT*D'R5()]%);QOKRR35];7,:.(JX9OV5T%A<#05"G>[WG-.3UE*VGDM$DCBJ59U9^GM=45!J?BJ6WE"R6UM-9C['9[U M#2QW-U-@1M"TGY]QOGM&I".3X2HI\LU/$RB[Q3C\-)-:-J7O3MLU%;WMZ>78 M:47[>:Y=+03TWWE^B[ZOL?DSXZ_Y'GQM_P!CAXH_]/M_7Z-A/]TPG_7FE_Z; MB>5/XY_XG^;/Z,/V%_\`DU3X1_\`8+US_P!2O7J_$N+?^2AS+_'3_P#3-,^A MP7^ZTO1_^E,]'_:3_P"3??C3_P!DQ\:?^F"^KAR+_DX_FQW[#?_`")?[7O_`&0C5/\`TW>):.+/]ZX: M_P"P^'_I5(6"^#%_]>G^I^>1_P!2?^N1_P#0*^TZG`?UP?#K_DGW@3_L3?#' M_IDL:_G#'?[[B_\`K]5_].2/JJ?\.'^&/Y(\I_:C^!\'Q^^$&O>!XI(;3Q#; MR0Z_X/OI\+#:>)=+28VD=P^,QV=Y!/=6,S#[L=ZTF&,8!]#A_-GDV94<6TW0 M=Z=:*W=*=N:WG%I3CW<;=3+$T%7HR@M)+6/2S7^>J^9_-G!-X]^#'Q!AF$>I M^"OB'X"UM)EBN8?*OM*U2SRVX=AN:..Z<#)"D#&/A:WA MYAW5;P^93I46[\DZ2G**[*2G!/U<4>E',Y)6=%$]'CE71]%%ZT8N)(A.SS:AJER8X4DNIB781I' M&D:`)7UN39'@LBHSI812=2I9U:TVN>?+>R=K*,(W;45HKMMMZG#7Q%2O).=H MJ/PQ6RO^OF?L!_P3S_9QU#X0>`M4\?>+M+;2O&WQ'2R:'3+F#R;[0?"5GOFT MRRNT(#6]_?7$SWL\#`&-5LXW`EB=5_-.-,[AF.,IX/"U.?"8'FO)/W:E:6DI M1[QBERQ?5\S6C3/6R_#NA!SDN6=3IM:/3YO=_(_1.OBCT`H`*`&2Q1S1R0S1 MI+#*CQ2Q2HLD&;NZ,4_*\?P32-WPY^RG^SQX4DADTG MX4^&7>WP83K*WWB18R.0R1^([R^13G!R%'05C7XASJNFJF858I[\G+2_]-1@ MQQPN'A\-):=[O\[GO%C86.E6L5CIEE::;96Z[8+.QMH;.U@7^[%;VZ)'&OLJ MBO(G.W4S%S!X4UA6T=7;)8II&M MVU]';J6.=EN\"#HJ@<#Z[!\<9WA8J%65+&1CUJPM/_P.FX-^LDVSBGEV'?PI MT_\`"]/N=[?(\J@_X)4?#9)E:?XJ^/I8`V6ACT_PW!(RY^Z)C92!#COL/TKT M7XA8ZUHY=AXOOS57;YB7Z'T;\+_P!A+]G3X6WUMK%KX5N? M%^NV3QS6NJ^.KX:]]EN(^5GM=*$$&F0RAOF5_L3.I`*L",UX>/XNSO'0E2>( M6$HRNG##Q]G=/HYW=1KRYK/L=%+`X>BTU'FE'9RUM\M%^!]B``````````8` M`X``'05\R=9\/ZE_P3P_9DU34=0U6\\.^)VO-3O[S4KMD\9Z[$C75_7X:[?*T[W M^)]3ZJ^''P]\,_"GP7H?@#P=;W-IX;\.0W$&EV]Y>3ZAKO^IK>+?"^D>-?"_B#P?KT4TVB>)M'U#0M6AMYY+2>33]3MI+2[CAN8 M2'MY&AE<"1"&4G(Y%98;$5,)B*.)HM1JX:<:D&TFE*+4E=/1JZVZCE%2C*#^ M&2::VT>_H?&7_#N']EP8`\.>*<#I_P`5MKXZ?]O-?4?Z[Y^O^7U+3_IQ3_R. M/^S\-_++_P`"9ZA\5OV0?@G\9M9T;7O'>CZW>:CH'ARQ\*Z=)8>)-5TN./1] M.N+NYM8I(;295EF$M[<$RL"S!@"?E%<&7<2YKE5*K1P=2G"G5JRJR4J4)/GD MDFTVM%:*TV-:N$HU'%SB[Q7*K-K3Y>HOPY_9"^"?PKT_QSIG@_1];M+3XB>& MYO"?B=;SQ)JE^]SHT\5W#)#:OW'[V+:PW`Y^448WB7-W;_P`( MWXJQC;_R.VO],8_Y^?2N_P#UXX@_Y_TO_!%/_(R_L[#?RR_\"9]P:5IMKHVE MZ;H]BKI8Z386>FV:2.TKI:V-O':VZO(Y+2.(8D!9N21D\FOE*DY5:DZL_CJ2 ME*5M-9-MZ=-6=J2BE%;15E\B_4#/#_B_^SE\'OCE;QI\0_!]GJ.I6T)@L?$5 MC)+I/B2PC)R([?6;%HYG@!R1!<&>$%B?+R2:];+,[S/)Y/ZCB73IR=Y4Y)2I M-]W"5TGYQM+S,:N'HUE^\AJMFM&OFO\`ACXUO/\`@EE\&I+PRV/CWXE6-EO8 MBR>Y\.WCJIZ(MW)H2MQZLC$]Z^GAX@YI&-I8/"REW2J1_P#)54M^1Q_V91OI M.:7;3_(]_P#A'^P_^S_\'=3M?$&D^&[SQ/XFL766QU[QK>KK=QI\ZCBXTZP% MO!I]CE@J%!IQCS26SEK;T6B7W'UW7S9UA0`4`%`'__V3\_ ` end